Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Low-risk Myelodysplastic Syndromes”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT00467610
What this trial is testing

Phase 2, Open-Label, Multi-Dose Study of Panhematin in Patients With MDS

Who this might be right for
Myelodysplastic Syndrome
Rush University Medical Center 6
Testing effectiveness (Phase 2)Study completedNCT03900715
What this trial is testing

An Efficacy and Safety Study of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in Japanese Subjects Who Are Not Requiring Red Blood Cell Transfusion

Who this might be right for
Myelodysplastic Syndromes
Celgene 21
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07153497
What this trial is testing

Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic Syndrome
National Cancer Institute (NCI) 132
Testing effectiveness (Phase 2)Study completedNCT01338337
What this trial is testing

Study of Vidaza (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) Without the 5q Deletion and Transfusion Dependent Anaemia

Who this might be right for
Myelodysplastic Syndrome (MDS)
Asociación Andaluza de Hematología y Hemoterapia 40
Testing effectiveness (Phase 2)Ended earlyNCT01422486
What this trial is testing

Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndrome (MDS)
Telik 2
Large-scale testing (Phase 3)Study completedNCT00179621
What this trial is testing

Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality

Who this might be right for
Myelodysplastic Syndromes
Celgene Corporation 205
Testing effectiveness (Phase 2)Looking for participantsNCT06778187
What this trial is testing

Oral-ATO for TP53-mutated Myeloid Malignancies

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic NeoplasmChronic Myelomonocytic Leukemia+2 more
The University of Hong Kong 30
Not applicableEnded earlyNCT00062231
What this trial is testing

Moxifloxacin Compared With Ciprofloxacin/Amoxicillin in Treating Fever and Neutropenia in Patients With Cancer

Who this might be right for
Chronic Myeloproliferative DisordersFever, Sweats, and Hot FlashesInfection+8 more
European Organisation for Research and Treatment of Cancer - EORTC 351
Early research (Phase 1)Study completedNCT01895842
What this trial is testing

Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Who this might be right for
Leukemia
M.D. Anderson Cancer Center 31
Early research (Phase 1)Study completedNCT01496495
What this trial is testing

ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes

Who this might be right for
Myelodysplastic Syndromes
Array Biopharma, now a wholly owned subsidiary of Pfizer 71
Testing effectiveness (Phase 2)Study completedNCT01272245
What this trial is testing

Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

Who this might be right for
Leukemia
M.D. Anderson Cancer Center 36
Testing effectiveness (Phase 2)Study completedNCT01772420
What this trial is testing

Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia

Who this might be right for
Adult Myelodysplastic SyndromeAnemiaChronic Myelomonocytic Leukemia
Albert Einstein College of Medicine 52
Very early researchUnknownNCT05687513
What this trial is testing

Clinical Efficacy and Mechanism of Yisui Granule in Treatment of Low and Medium Risk Myelodysplastic Syndrome Through Demethylation

Who this might be right for
MDS
Dongzhimen Hospital, Beijing 76
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07738510
What this trial is testing

Evaluate Ofirnoflast in Adults With Very Low- to Intermediate-risk Myelodysplastic Syndromes Requiring Transfusions

Who this might be right for
Myelodysplastic SyndromesAnemia
Halia Therapeutics, Inc. 50
Large-scale testing (Phase 3)Study completedNCT03268954
What this trial is testing

Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)

Who this might be right for
Myelodysplastic SyndromeLeukemia, Myelomonocytic, ChronicLeukemia, Myeloid, Acute
Takeda 454
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05554419
What this trial is testing

Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)

Who this might be right for
Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia Arising From Previous Myeloproliferative Neoplasm+2 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Study completedNCT03824080
What this trial is testing

Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes

Who this might be right for
Acute Myeloid LeukemiaHigh-risk Myelodysplastic SyndromeLow-risk Myelodysplastic Syndrome
GWT-TUD GmbH 45
Testing effectiveness (Phase 2)Ended earlyNCT00542828
What this trial is testing

Rabbit Anti-thymocyte Globulin in the Treatment of Patients With Low to Intermediate-1 Risk Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndrome (MDS)
Genzyme, a Sanofi Company 16
Testing effectiveness (Phase 2)UnknownNCT00003681
What this trial is testing

Amifostine With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome

Who this might be right for
AnemiaMyelodysplastic Syndromes
European Organisation for Research and Treatment of Cancer - EORTC 50
Not applicableStudy completedNCT02378701
What this trial is testing

Interventional Validation of an MDS-Specific Measure of Quality of Life: Assessing the Responsiveness of the Quality of Life in Myelodysplasia Scale (QUALMS-1) to Different Hypomethylating Agent Regimens for Low and Intermediate Risk Disease

Who this might be right for
Leukemia
M.D. Anderson Cancer Center 102
Next Page
184